SRC and acute lymphoblastic leukemia: To test whether STAT3 is the main target of the SRC signaling pathway in pre-B ALL, we treated NALM6 cells with GZD824, SRC inhibitor (KX2-391), STAT3 inhibitor (HO-3867), or DMSO.